American Vanguard’s Q4 2025 Call: Revenue-EBITDA Divergence, $100M Timeline Shifts Clash

Date of Call: Mar 16, 2026

Financials Results

• Revenue: $515M, down 6% YOY
• Gross Margin: 29%, increased YOY

Guidance:

• Adjusted EBITDA for 2026 expected to be $44M to $48M.
• Sales for 2026 expected to be $530M to $550M.
• Company estimates potential for at least $100M additional annual revenue globally from new products over the medium term (by 2031).

Business Commentary:

Financial Performance and Challenges:

• American Vanguard reported adjusted EBITDA of $39.2 million for 2025, slightly better than the previous year but falling short of the target range of $40 million to $44 million.
• The shortfall was primarily due to sluggish sales in the fourth quarter, particularly in international markets affected by a drought in Australia and elevated channel inventories in Mexico, as well as lower demand for specific products like metam in the U.S.

Cost Management and Operational Improvements:

• The company managed to cut more costs than initially estimated, contributing to the improvement in adjusted EBITDA despite lower sales.
• Initiatives included hiring experienced supply chain leaders, improving safety metrics, and focusing on new product development while reducing manufacturing and operating costs.

Strategic Restructuring and Facility Rationalization:

• American Vanguard decided to rationalize its Los Angeles manufacturing facility, expecting annual savings of at least $4 million.
• The decision was driven by the need to improve competitiveness, as the L.A. plant was the oldest and no longer competitive, with plans to move additional volumes to the Axis, Alabama site.

New Product Development and Growth Strategy:

• The company launched one new product, Duro-LQ, in 2026 and expects to launch five new products in North America that year, with plans to register at least 25 new products internationally by 2031.
• This focus on product development is aimed at generating at least an additional $100 million in annual revenue globally over the medium term, enhancing the margin profile with higher-margin contributions.

Debt Refinancing and Financial Stability:

• American Vanguard refinanced its debt with two term loans from Centerbridge Partners and BMO, providing financial flexibility despite higher interest rates.
• This move was aimed at paying down expiring credit facilities and positioning the company for future growth, with a focus on improving operations to demonstrate higher earnings power.

Sentiment Analysis:

Overall Tone: Positive

• "I am pleased with the progress that has been made at American Vanguard." "We believe future earnings power is substantially higher and will allow the company to pay down its debt and make investments in areas which will lead to long-term growth." "We will generate greater sales, more profitability and cash flow, creating a long-term value for our shareholders."

Q&A:

• Question from Michael Harrison (Seaport Research Partners): Was hoping that maybe we could start just with Q4 and kind of coming in below expectations on the revenue line as well as the EBITDA line... I was hoping you could just give a little bit more color on what dragged down revenue. And in terms of the margin performance, with that in line with expectations, and it was just a revenue shortfall that led to the EBITDA shortfall, or were there some issues on the cost side as well?
  Response: The revenue shortfall was due to both international (drought in Australia, channel inventory in Mexico) and domestic factors (lower potato acres, metam sales, softer insecticide demand). Cost containment and manufacturing improvements were in good shape.

• Question from Michael Harrison (Seaport Research Partners): And in terms of your long-term transformation plans, those have been in place for a while. I'm just kind of curious on how the L.A. closure and the headquarter relocation fit in? Are those -- were those kind of contemplated when you initially came out with this 15% EBITDA margin target, or should we think of these as maybe accelerating the process of achieving that 15% target?
  Response: The LA facility rationalization and headquarters move were not part of the original transformation plan. They are new initiatives undertaken later to improve cost structure.

• Question from Michael Harrison (Seaport Research Partners): It is great to see that you guys have the new term loans in plan -- in place. But I'm curious, are there any cash proceeds associated with the closure of the Los Angeles facility or the headquarter migration?
  Response: No proceeds from sale of LA facility assets; it will remain as a smaller formulation/warehousing site. The HQ move saves ~$0.5M annually in leasing costs.

• Question from Michael Harrison (Seaport Research Partners): And then just in terms of cash flow, I understand the prepayments were unusually low in Q4 and that kind of dragged down what cash flow looks like in '25. But I'm curious with the software that you're planning to roll out and your expectations around working capital for 2026. I'm just curious, is it possible that we get to free cash flow positive in 2026 given your expectations for CapEx in the $5 million to $10 million range.
  Response: CEO believes free cash flow positive is achievable in 2026.

• Question from Rosemarie Morbelli (Gabelli Funds): When you talked about the $100 million of the midterm coming in from new products... Can you give us a little more details as to what you expect? I mean is that going -- are your new products also coming from fungicides or herbicide? And then what is your definition of midterm?
  Response: New products are primarily from insecticides and herbicides. 'Midterm' is defined as 2030-2031, with launches starting around 2028, requiring ~3 years of regulatory process.

• Question from Rosemarie Morbelli (Gabelli Funds): And you talked about the high future earning powers of the company. So currently, based on the midpoint of 2026 expectations, your EBITDA margin is about 8.5%. So how high can it get? And what type of top line growth do you need to get there in addition to all of the steps you are taking lowering cost.
  Response: Long-term goal remains 15% EBITDA margin, achievable with 4-6% sales CAGR and continued cost reduction through manufacturing efficiencies and cost control.

Contradiction Point 1

Q4 Revenue and EBITDA Performance

It involves differing primary causes for Q4 revenue shortfall and EBITDA pressure, impacting understanding of business performance and future outlook.

Michael Harrison (Seaport Research Partners) - Michael Harrison (Seaport Research Partners)

2025Q4: The Q4 shortfall was due to both international and domestic sales declines. - Douglas Kaye(CEO)

What factors contributed to the Q4 revenue and EBITDA decline—was it primarily a revenue shortfall or also margin issues? - Michael Harrison (Seaport Research Partners)

2025Q3: U.S. crop performed very well in Q3... A cloud remains due to trade tensions affecting soybeans. - Douglas Kaye(CEO), David Johnson(CFO)

Contradiction Point 2

Free Cash Flow Expectations

Contradiction on the expected free cash flow position for the upcoming year, affecting financial planning and investor expectations.

Michael Harrison (Seaport Research Partners) - Michael Harrison (Seaport Research Partners)

2025Q4: Based on the 2026 adjusted EBITDA projections and CapEx expectations... the company believes it should achieve a favorable cash flow position and potentially turn positive. - Douglas Kaye(CEO)

Will the closure of the Los Angeles facility, headquarters migration, software rollout, and working capital expectations contribute to positive free cash flow by 2026? - Charles Rose (Cruiser Capital Advisors)

2025Q3: With EBITDA of $40-44M, CapEx of ~$5-6M... free cash flow is estimated around $20M. - Douglas Kaye(CEO)

Contradiction Point 3

Timeline for Achieving $100M in Additional Annual Revenue

Contradiction on the expected timeline for new products to contribute to revenue growth, impacting strategic planning and investor confidence.

Rosemarie Morbelli (Gabelli Funds) - Rosemarie Morbelli (Gabelli Funds)

2025Q4: The $100 million is expected from new products... "Midterm" means around 2030-2031... - Douglas Kaye(CEO), David Johnson(CFO)

Can you provide details on the expected $100 million in annual revenue from new products, including the timing (midterm) and confidence level in meeting that target? - Wayne Pinsent (The Gabelli Healthcare & Wellness Trust)

2025Q3: New products are in various stages, with fruition expected starting around 2028... - Douglas Kaye(CEO)

Contradiction Point 4

15% EBITDA Margin Target Timeline and Achievement

Contradiction on whether the 15% margin target is a near-term goal or a long-term aspiration, affecting perceptions of management's strategic focus and financial targets.

Rosemarie Morbelli (Gabelli Funds) - Rosemarie Morbelli (Gabelli Funds)

2025Q4: The long-term goal remains 15% EBITDA margin. This will be driven by... and reducing the cost structure. - Douglas Kaye(CEO) and David Johnson(CFO)

Can you provide more details on the expected $100 million in additional annual revenue from new products and the path to higher EBITDA margins beyond the 2026 midpoint of ~8.5%? - Wayne Pinsent

2025Q2: The Q2 margin improvement was a culmination of several positive factors... It represents the target the company is striving for, with the long-term goal of reaching 15% EBITDA margins. - Douglas Kaye(CEO)

Contradiction Point 5

Comfort and Certainty Regarding New Product Revenue Target

Contradiction on the level of confidence expressed in achieving the $100M new product revenue target, impacting investor trust in management's guidance.

What are your expectations for revenue growth in the next quarter? - Rosemarie Morbelli (Gabelli Funds)

2025Q4: The company is confident in the $100 million estimate based on the CEO's experience. - Douglas Kaye(CEO)

Can you provide more details on the expected $100 million in additional annual revenue from new products and the path to higher EBITDA margins beyond the 2026 midpoint of ~8.5%? - Wayne Pinsent

2025Q2: There is ongoing, internal initiative to find a strategic placement for the technology. Discussions are in progress with some parties, but nothing of public substance has been finalized yet. - Douglas Kaye(CEO)